# Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

> **NCT03872206** · PHASE1 · COMPLETED · sponsor: **Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 95 (actual)

## Conditions studied

- Advanced Cancers Associated With Mesothelin Expression

## Interventions

- **BIOLOGICAL:** HPN536 Fixed IV 6 to 560 ng/kg
- **BIOLOGICAL:** HPN536 1 Prime Step IV 600-1200 ng/kg Target
- **BIOLOGICAL:** 2 Prime Step IV 900-14000 ng/kg Target

## Key facts

- **NCT ID:** NCT03872206
- **Lead sponsor:** Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2023-01-04
- **Final completion:** 2023-01-04
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03872206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03872206, "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03872206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*